These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37679600)

  • 1. Combined immunochemotherapy achieving targeted co-delivery of chlorogenic acid and doxorubicin by sialic acid-modified liposomes enhances anti-cancer efficacy.
    Zhu S; Li X; Luo Z; Ding M; Shi S; Zhang T
    Drug Deliv Transl Res; 2024 Mar; 14(3):718-729. PubMed ID: 37679600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects.
    Li X; Zhu S; Yin P; Zhang S; Xu J; Zhang Q; Shi S; Zhang T
    Drug Deliv; 2021 Dec; 28(1):1849-1860. PubMed ID: 34515617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylserine and/or Sialic Acid Modified Liposomes Increase Uptake by Tumor-associated Macrophages and Enhance the Anti-tumor Effect.
    Xu Z; Li J; Yan N; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2024 Jun; 25(5):125. PubMed ID: 38834759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal Doxorubicin: the Sphingomyelin/Cholesterol System Significantly Enhances the Antitumor Efficacy of Doxorubicin.
    Meng X; Zhang H; Chen L; Wang M; Zhang K; Liu X; Deng Y; Song Y
    AAPS PharmSciTech; 2023 Feb; 24(2):64. PubMed ID: 36759405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy.
    Ding J; Zhao D; Hu Y; Liu M; Liao X; Zhao B; Liu X; Deng Y; Song Y
    Int J Pharm; 2019 Nov; 571():118706. PubMed ID: 31593811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted delivery of zoledronic acid through the sialic acid - Siglec axis for killing and reversal of M2 phenotypic tumor-associated macrophages - A promising cancer immunotherapy.
    Tang X; Sui D; Liu M; Zhang H; Liu M; Wang S; Zhao D; Sun W; Liu M; Luo X; Lai X; Liu X; Deng Y; Song Y
    Int J Pharm; 2020 Nov; 590():119929. PubMed ID: 33010395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sialic acid-decorated liposomes enhance the anti-cancer efficacy of docetaxel in tumor-associated macrophages.
    Tran NP; Tran P; Yoo SY; Tangchang W; Lee S; Lee JY; Son HY; Park JS
    Biomater Adv; 2023 Nov; 154():213606. PubMed ID: 37678087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-α-tocopherol polyethylene glycol 1000 succinate-modified liposomes with an siRNA corona confer enhanced cellular uptake and targeted delivery of doxorubicin via tumor priming.
    Tan X; Fang Y; Ren Y; Li Y; Wu P; Yang X; Liu W
    Int J Nanomedicine; 2019; 14():1255-1268. PubMed ID: 30863058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy.
    Li C; Qiu Q; Gao X; Yan X; Fan C; Luo X; Liu X; Wang S; Lai X; Song Y; Deng Y
    J Control Release; 2021 Sep; 337():393-406. PubMed ID: 34171446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-penetrating corosolic acid liposome as a functional carrier for delivering chemotherapeutic drugs.
    Li X; Widjaya AS; Liu J; Liu X; Long Z; Jiang Y
    Acta Biomater; 2020 Apr; 106():301-313. PubMed ID: 32081779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-tumor and renoprotection study of E-[c(RGDfK)
    Zhang B; Zhang Y; Dang W; Xing B; Yu C; Guo P; Pi J; Deng X; Qi D; Liu Z
    J Nanobiotechnology; 2022 Sep; 20(1):425. PubMed ID: 36153589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the antitumor effect of dexamethasone palmitate and doxorubicin co-loaded liposomes modified with a sialic acid-octadecylamine conjugate.
    Sun J; Song Y; Lu M; Lin X; Liu Y; Zhou S; Su Y; Deng Y
    Eur J Pharm Sci; 2016 Oct; 93():177-83. PubMed ID: 27539143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
    Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
    Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity.
    Zhou S; Zhang T; Peng B; Luo X; Liu X; Hu L; Liu Y; Di D; Song Y; Deng Y
    Int J Pharm; 2017 May; 523(1):203-216. PubMed ID: 28336455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sialic acid-modified doxorubicin liposomes target tumor-related immune cells to relieve multiple inhibitions of CD8
    Du Z; Sui D; Xin D; Tang X; Li M; Liu X; Deng Y; Song Y
    J Liposome Res; 2024 Sep; 34(3):464-474. PubMed ID: 38196168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anticancer efficacy of pixantrone-loaded liposomes decorated with sialic acid-octadecylamine conjugate.
    She Z; Zhang T; Wang X; Li X; Song Y; Cheng X; Huang Z; Deng Y
    Biomaterials; 2014 Jun; 35(19):5216-25. PubMed ID: 24703714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacodynamics of liposomes modified with different chain length of sialic acid derivatives].
    Song YZ; Huang ZJ; Luo X; Wang MJ; Zheng JH; Shi J; Deng YH
    Yao Xue Xue Bao; 2016 Feb; 51(2):316-24. PubMed ID: 29856587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Derma roller® microneedles-mediated transdermal delivery of doxorubicin and celecoxib co-loaded liposomes for enhancing the anticancer effect.
    Ahmed KS; Shan X; Mao J; Qiu L; Chen J
    Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():1448-1458. PubMed ID: 30889679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
    Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
    Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M; Wang J; Bai J; Li X; Tian C; Liu Z; Zheng C; Clark AR; Cheng X; Liao X; Wu S; Lee RJ; Zhou X
    Mol Pharm; 2023 Apr; 20(4):1951-1963. PubMed ID: 36952242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.